TMCnet News
Tizona Announces Initiation of Phase 1/1b Study with Novel Cancer Immunotherapy TTX-030 and First Public Presentation of Pre-Clinical Data with TTX-030 at AACR 2019SOUTH SAN FRANCISCO, Calif., March 27, 2019 (GLOBE NEWSWIRE) -- Tizona Therapeutics, Inc., a privately held immunotherapy company, today announced that it has begun enrolling patients in its Phase 1/1b clinical study evaluating TTX-030, a first-in-class, fully human, anti-CD39 antibody for the treatment of cancer. The Phase 1/1b study will evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of TTX-030 as a single agent, in combination with an approved anti-PD-1 immunotherapy, and in combination with standard chemotherapies in adults with advanced cancers. More information on the study is available at clinicaltrials.gov [TTX-030-001]. “Enrolling patients in our Phase 1/1b study represents an important milestone for Tizona as we translate our TTX-030 research efforts into the clinic,” said Scott Clarke, CEO of Tizona. “We believe that targeting CD39, which initiates extracellular ATP metabolism, could play an important role in addressing cancer progression and relapse.” In addition, the first public presentation of TTX-030 pre-clinical data will be shared as a poster presentation at the American Association of Cancer Research (AACR) 2019 (#AACR2019) annual meeting in Atlanta, Georgia, March 29 – April 3. AACR oster Presentation Details: Date and Time: April 3, 2019 8:00 am – 12:00 pm ET Location: Georgia World Congress Center, Exhibit Hall B, Poster Section 25 Session Category: Immunology Session Title: Tumor Immune Microenvironment (Session PO. IM02.10 Section 25) Abstract Number: 5012 About TTX-030, the Adenosine Axis, and the Tumor Microenvironment TTX-030 is being developed in collaboration with AbbVie. Contact: |